The test can pick up several types of cancer, including pancreatic and ovarian, years before symptoms appear.

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

In the largest study of its kind to date, researchers find more than 850 rare, heritable genetic alterations that can predispose humans to cancer.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The University of Minnesota researcher is on the front lines in the fight against the disease.

Researchers were able to slow tumor growth in a mouse model of human ovarian cancer. 

The new diagnostic works by identifying cancer-associated proteins and DNA in patient blood.

Family members of Lacks, the donor behind the widely used HeLa cell line, are planning to sue Johns Hopkins University.

A jury recently awarded $72 million in a talcum-powder–ovarian cancer case, but the data linking the hygiene product to disease risk are inconclusive.

Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.